Table 2.
Comparison of Human Heart Failure Drugs and the Newly Identified Compounds on AA-Induced Heart Failure
| Optimal dose (μM) | Attenuation efficacy (%) | Functional time window (hpf) | Toxicity | |
|---|---|---|---|---|
| Human heart failure drugs | ||||
| Furosemide |
5 |
∼15 |
ND |
No |
| Levosimendan |
5 |
∼30 |
ND |
No |
| Spironolactone |
20 |
∼40 |
ND |
Body curvature, tail necrosis |
| Warfarin |
1 |
∼30 |
ND |
Necrosis |
| Newly identified compounds | ||||
| NS398 |
10 |
∼50 |
24–42 |
No |
| MEK-I |
1 |
∼60 |
24–30 |
Wavy notochord, albinisma |
| C25 |
10 |
∼80 |
24–36 |
Body curvatureb |
| A11 | 10 | ∼90 | 24–40 | Albinism |
a
Only in early embryos.
b
Only occasionally.
MEK-I, mitogen-activated protein kinase kinase inhibitor.